

PATENT APPLICATE File No: 97

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Paul O. Sheppard, Laura J. Jelinek

Serial No.

09/852,472

Group Art Unit

1646

Examiner

Pak, M.

Filed

: May 10, 2001

For

MAMMALIAN NEURO-GROWTH FACTOR LIKE PROTEIN

Date Submitted

November 21, 2002

AMENDMENT FEE TRANSMITTAL

BOX NON-FEE AMENDMENT Commissioner for Patents Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-mentioned application. The fee required to be filed with the accompanying amendment has been calculated as shown below:

CLAIMS AS AMENDED

	Claims Remaining After	Highest No. Covered by Previous Payments	Present Extra	Extra Rate	Fee
	Amendment	-20	0	\$9.00	\$000.00
Total	1	-3	0	\$42.00	\$000.00
Independent 1 -3 0 1st Presentation of Multiple Dependent Claim				\$140.00	\$000.00
1st Presentation of Multiple Dependent Statis			Total	\$000.00	

Applicants claim small entity status. Please charge any required fee to ZymoGenetics, Inc., Deposit Account No. 26-0290. A duplicate of this sheet is enclosed. Respectfully submitted,

Paul G. Lunn, Esq. Registration No. 32,743



CERTIFICATE OF MAILING [37 CFR 1.8(a)]

reby certify that this correspondence and all items mentioned herein are leing deposited with the United States Postal Service on the date shown belowith sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, Washington, DC 20231 on November 22, 2002

Signature Lara Russell

Docket No. 97-28C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Shepard et al.

Examiner: Pak, M.

Serial No. 09/852,472

Art Unit 1646

Filed: May 10, 2001

November 22, 2002

Paper No. 6

For: MAMMALIAN NEURO-GROWTH FACTOR LIKE PROTEIN

Commissioner of Patents

Washington, D.C. 20231

AMENDMENT

Dear Sir:

This is in response to the Office Action dated October 1, 2002. Accompanying the present response is a request for a 1-month extension of time, extending the period for response from November 1, 2002 to December 1, 2002.

Please amend the application as follows:

IN THE CLAIMS:

Please cancel claims 1-15 without prejudice and insert the following new claim 16.

AI

Claim 16 (New) An isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO:3.